Acute neonatal effects following prenatal venlafaxine exposure
Ugeskrift for Læger · 19.10.2026 · 1-4
DOI: 10.61409/v03260181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ugeskrift for Læger, online erschienen am 19.10.2026. Verfasst von Chrishanthi Harideep und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Venlafaxine is a serotonin-noradrenaline reuptake inhibitor. Intrauterine exposure may cause neonatal withdrawal symptoms known as poor neonatal adaptation syndrome (PNAS). In this case report, we present a term newborn with respiratory distress and neurological hyperexcitability after birth following maternal venlafaxine treatment. Evaluation excluded infectious and neurological causes, and symptoms resolved in days. PNAS should be considered despite early symptoms. Regional variation in observation practices may affect recognition of PNAS, underscoring the need for awareness of the condition.
Zitieren
APA
Harideep, C., Damkier, P., & Honoré, K. D. (2026). Acute neonatal effects following prenatal venlafaxine exposure. Ugeskrift for Læger, 1-4. https://doi.org/10.61409/v03260181
Vancouver
Harideep C, Damkier P, Honoré KD. Acute neonatal effects following prenatal venlafaxine exposure. Ugeskrift for Læger. 2026:1-4. doi:10.61409/v03260181
BibTeX
@article{Harideep2026,
author = {Harideep, Chrishanthi and Damkier, Per and Honoré, Karina Dyrvig},
title = {Acute neonatal effects following prenatal venlafaxine exposure},
journal = {Ugeskrift for Læger},
year = {2026},
pages = {1--4},
doi = {10.61409/v03260181}
}
EUVIMED